1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,260 | 3,380 | 21.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 29.11. | HAOHAI BIOTEC (06826): ANNOUNCEMENT IN RELATION TO ADJUSTMENTS TO THE NUMBER OF RESTRICTED SHARES AND THE GRANT PRICE UNDER THE 2021 RESTRICTED A SHARE ... | - | HKEx | ||
| 28.11. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 21.11. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 13.11. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 05.11. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 28.10. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 25.10. | HAOHAI BIOTEC (06826): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 2 | HKEx | ||
| 25.10. | HAOHAI BIOTEC (06826): WORKING RULES OF THE STRATEGY AND SUSTAINABLE DEVELOPMENT COMMITTEE OF THE BOARD | 1 | HKEx | ||
| 25.10. | HAOHAI BIOTEC (06826): WORKING RULES OF THE AUDIT COMMITTEE OF THE BOARD | - | HKEx | ||
| 25.10. | HAOHAI BIOTEC (06826): 2024 THIRD QUARTERLY REPORT; AMENDMENTS TO THE WORKING RULES OF THE STRATEGY COMMITTEE AND THE AUDIT COMMITTEE; AND CHANGE OF NAME ... | 3 | HKEx | ||
| 15.10. | HAOHAI BIOTEC (06826): DATE OF BOARD MEETING | - | HKEx | ||
| 10.10. | HAOHAI BIOTEC (06826): ANNOUNCEMENT ON ADJUSTMENT OF SHARE PRICE CAP FOR REPURCHASE OF A SHARES | 1 | HKEx | ||
| 20.09. | Dividendenbekanntmachungen (20.09.2024) | 6.549 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECON GROUP INC CA00762V1094 0,19 CAD 0,1255 EUR ALEXANDER & BALDWIN INC US0144911049 0,2225 USD 0,1993 EUR ALLEGION PLC IE00BFRT3W74 0... ► Artikel lesen | |
| 19.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 13.09. | HAOHAI BIOTEC (06826): INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2024 (UPDATED) | 1 | HKEx | ||
| 13.09. | HAOHAI BIOTEC (06826): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 13.09. | HAOHAI BIOTEC (06826): POLL RESULTS OF EGM, A SHAREHOLDERS' CLASS MEETING AND H SHAREHOLDERS' CLASS MEETING, AND 2024 INTERIM PROFIT DISTRIBUTION PLAN | 1 | HKEx | ||
| 05.09. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 02.09. | HAOHAI BIOTEC (06826): (REVISED) NEXT DAY DISCLOSURE RETURN | 1 | HKEx |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 1,971 | +0,51 % | Valneva: Kooperation für Chikungunya-Impfstoff in Asien | Valneva hat eine exklusive Lizenzvereinbarung mit dem Serum Institute of India (SII) getroffen, um seinen Chikungunya-Impfstoff in Asien verfügbar zu machen. Die Kooperation ermöglicht den Zugang zu... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| STRYKER | 348,90 | -0,17 % | Reasons to Invest in Stryker Corp. (SYK) | ||
| REGENERON PHARMACEUTICALS | 675,00 | +0,21 % | Regeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or aflibercept injection 8 mg... ► Artikel lesen | |
| EXACT SCIENCES | 52,82 | -7,24 % | Exact Sciences Corp.: Exact Sciences Advances Breast Cancer Care with the Oncotype DX test and Genomic Profiling Research at SABCS 2024 | New data supports the value of the Oncotype DX Breast Recurrence Score test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally
Exact Sciences... ► Artikel lesen | |
| CSL | 167,64 | -0,02 % | Why CSL and these excellent ASX retirement shares could be buys in 2025 | ||
| CANSINO BIOLOGICS | 3,720 | -3,12 % | CANSINOBIO (06185): VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I/II CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT IN PHASE I CLINICAL TRIAL ... | ||
| BEIGENE LTD ADR | 165,00 | -2,94 % | BeiGene, Ltd.: BeiGene gibt globale Lizenzvereinbarung für MAT2A-Inhibitor bekannt | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, das seinen Namen in BeOne Medicines Ltd. ändern wird, gab heute bekannt, dass es mit CSPC Zhongqi Pharmaceutical... ► Artikel lesen | |
| BIOMERIEUX | 100,90 | -1,08 % | Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com | The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The... ► Artikel lesen | |
| SINO BIOPHARM | 0,385 | -1,43 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - PERMISSION OBTAINED TO SUBMIT MARKETING APPLICATION FOR THE INDICATION OF BENMELSTOBART INJECTION IN COMBINATION ... | ||
| ZAI LAB LTD ADR | 25,600 | -0,78 % | ZAI LAB (09688): NEXT DAY DISCLOSURE RETURN | ||
| CSTONE PHARMACEUTICALS | 0,260 | -4,41 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES FIRST PATIENT ENROLLED IN THE GLOBAL MULTICENTER PHASE IB CLINICAL TRIAL OF CS5001 ... | ||
| CASI PHARMACEUTICALS | 2,710 | -2,87 % | CASI Pharmaceuticals, Inc. - 6-K, Report of foreign issuer | ||
| GENSCRIPT BIOTECH | 1,180 | -1,67 % | GENSCRIPT BIO (01548): COMPANY EXERCISES THE CONVERSION RIGHTS OF THE CONVERTIBLE BOND ISSUED BY PROBIO CAYMAN | ||
| 3SBIO | 0,730 | -3,95 % | 3SBIO (01530): (1) CANCELLATION OF TREASURY SHARES; AND (2) CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG |
SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,120 (+3,82 %) liegt der Kurs bei 3,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.
